EC expands Novavax' Nuvaxovid COVID-19 vaccine approval

13 September 2022

Yesterday, Nuvaxovid (NVX-CoV2373) COVID-19 vaccine was granted expanded conditional marketing authorization (CMA) in the European Union (EU) for use as a booster vaccine for adults aged 18 and older by the European Commission.

Developed by US biotech Novavax (Nasdaq: NVAX), Nuvaxovid has not been a major success in the covid vaccine space, in the second quarter of 2002 only generating $55 million of product sales by Novavax and $23 million of royalties, milestone, and adjuvant sales to license partners. The vaccine only gained US approval in July this year. By contrast, the leading COVID-19 vaccine, Comirnaty, earned Pfizer $8.85 billion sales in the 2022 second quarter.

With uptake of a second booster dose at only 7.5% in Europeans over the age of 18 according to the European Centre for Disease Prevention and Control’s latest figures, Novavax believes this is an opportune time for a discussion on the importance of expanded vaccination options in Europe, and the approval of Nuvaxovid in this context.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK